SLC5A2 and chronic kidney disease: To improve CKD patients’ prognosis, novel drugs have been discovered and most of them implemented in clinical practice, such as SGLT2 inhibitors (SGLT2-Is) as well as non-steroidal mineralocorticoid receptor antagonists (MRAs) [6,7,8].